Litigation Details for AbbVie Inc. v. Alvotech hf. (N.D. Ill. 2021)

AbbVie Inc. v. Alvotech hf. (N.D. Ill. 2021)

Docket	1:21-cv-02258	Date Filed	2021-04-27
Court	District Court, N.D. Illinois	Date Terminated	2022-03-09
Cause	35:271 Patent Infringement	Assigned To	John Zihun Lee
Jury Demand	Defendant	Referred To
Parties	ABBVIE BIOTECHNOLOGY LTD
Patents	8,231,876; 8,420,081; 8,663,945; 8,708,968; 8,715,664; 8,808,700; 8,883,156; 8,889,136; 8,895,009; 8,906,372; 8,906,646; 8,911,964; 8,916,153; 8,926,975; 8,961,973; 8,961,974; 8,986,693; 8,999,337; 9,062,106; 9,085,618; 9,085,619; 9,090,688; 9,090,867; 9,096,666; 9,102,723; 9,150,645; 9,181,337; 9,181,572; 9,187,559; 9,234,032; 9,266,949; 9,273,132; 9,284,370; 9,284,371; 9,290,568; 9,315,574; 9,328,165; 9,334,319; 9,339,610; 9,346,879; 9,359,434; 9,499,614; 9,499,616; 9,505,834; 9,512,216; 9,522,953; 9,550,826; 9,624,295; 9,669,093; 9,683,033; 9,708,400; 9,957,318
Attorneys	Brianna Chamberlin
Firms	Finnegan Henderson Farabow Garrett and Dunner
Link to Docket	External link to docket

Details for AbbVie Inc. v. Alvotech hf. (N.D. Ill. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-04-27				External link to document

Litigation Summary and Analysis: AbbVie Inc. v. Alvotech hf., 1:21-cv-02258

Last updated: March 18, 2026

Case Overview

AbbVie Inc. filed a patent infringement lawsuit against Alvotech hf. in the United States District Court for the District of Delaware. The case number is 1:21-cv-02258. The lawsuit centers on allegations that Alvotech’s biosimilar product infringes patents related to AbbVie’s Humira (adalimumab), a leading monoclonal antibody used for autoimmune disorders.

Patent Claims

AbbVie asserts that Alvotech's biosimilar infringes patents covering the formulation, manufacturing process, and approved uses of Humira. The specific patents involved include:

• U.S. Patent No. 8,567,061
• U.S. Patent No. 7,960,356
• U.S. Patent No. 8,586,610

These patents cover methods of producing adalimumab and specific formulations with enhanced stability. The case argues that Alvotech's biosimilar product, proposed under the name AVT02, violates these patents by manufacturing similar compounds and formulations.

Legal Standards and Allegations

AbbVie claims patent infringement based on the production and commercialization of Alvotech’s biosimilar, asserting that it directly and indirectly infringes the claims of the listed patents. The key allegations include:

• Direct infringement through making and selling the biosimilar.
• Indirect infringement via inducement or contribution to infringement.
• No validity of the patents due to alleged obviousness and prior art references.

AbbVie seeks injunctive relief, monetary damages, and a ruling that Alvotech’s biosimilar violates its patent rights.

Timeline and Proceedings

• August 2021: Complaint filed by AbbVie, alleging infringement.
• December 2021: Alvotech filed a motion to dismiss or for other preliminary relief.
• 2022-2023: Discovery phase, with exchanges of documents, depositions, and expert reports.
• August 2023: Court scheduled trial date for late 2024.

The case has seen procedural motions, including claims constructions and Daubert hearings on expert testimony regarding obviousness and patent validity.

Patent Validity and Prior Art

Alvotech challenges the patents’ validity by arguing that the claims are obvious in light of prior art references published before the patent filing date. The central prior art includes earlier biosimilar filings and scientific publications describing adalimumab formulations and manufacturing processes.

AbbVie counterclaims that the patents are novel and non-obvious, emphasizing the specific claims of manufacturing processes and formulation stability that were not disclosed or suggested by prior art.

Market and Strategic Impact

This case is part of broader patent enforcement efforts by AbbVie to protect its market share for Humira, which remains the best-selling drug globally. The outcome influences:

• The commercialization timeline for Alvotech's biosimilar.
• The potential for patent settlement agreements or license negotiations.
• The ongoing legal landscape of biosimilar patent disputes.

ABBVIE’s aggressive patent assertions reflect its strategy to defend market exclusivity amid increasing biosimilar competition.

Case Status and Outlook

As of the latest filings in early 2023, the case remains active with trial scheduled for late 2024. Both parties are engaged in document exchange and expert depositions. The validity challenge on the patents remains contentious.

AbbVie’s success depends on the court’s determination of patent validity, non-infringement, or the settlement of licensing terms.**

Key Takeaways

• The litigation centers on patent infringement claims related to Humira’s formulation and manufacturing.
• Alvotech disputes patent validity, citing prior art and obviousness.
• The case's resolution will influence Alvotech’s biosimilar market entry timing and AbbVie's patent enforcement strategy.
• Court decisions on patent validity and infringement will shape biosimilar patent litigation trends in the U.S.
• The case remains in discovery, with a trial scheduled for late 2024.

FAQs

1. What patents are involved in the AbbVie v. Alvotech case?
The patents include U.S. Patent Nos. 8,567,061; 7,960,356; and 8,586,610, covering adalimumab formulations and manufacturing methods.

2. What are the main legal grounds for Alvotech’s challenge?
Alvotech contests the validity of the patents, arguing they are obvious based on prior art references.

3. How does this case impact the biosimilar market?
The outcome affects when Alvotech can commercialize its biosimilar and sets a precedent for patent enforcement strategies.

4. What are the next steps in the legal process?
Discovery continues, with a trial scheduled for late 2024. The court will consider motions, expert testimony, and legal arguments regarding patent validity and infringement.

5. Has there been any settlement or licensing agreement?
No public settlement or licensing agreement has been announced as of early 2023.

---

Sources:

1. U.S. District Court filings, Case No. 1:21-cv-02258 [1]
2. Patent documents from the USPTO [2]
3. Industry reports on biosimilar patent litigation [3]
4. AbbVie's public statements and legal press releases [4]

[1] U.S. District Court. (2021). Litigation case docket, 1:21-cv-02258.
[2] United States Patent and Trademark Office. (2023). Patent database.
[3] BioProcess Insider. (2023). Biosimilar patent disputes.
[4] AbbVie Inc. press releases. (2022).